Parameters for the treadmill during the acclimatization period. by Wenbin Wu (292223)

Subjects:

Improvement effect of lactoferrin and Coenzyme Q10 on body composition of mice with sarcopenia. by Wenbin Wu (292223)

Subjects:

KEGG pathway enrichment analysis of lactoferrin and Coenzyme Q10 in sarcopenia. by Wenbin Wu (292223)

Subjects:

Effects of lactoferrin and Coenzyme Q10 on skeletal muscle of mice. by Wenbin Wu (292223)

Subjects:

Each group’s performance on behavioral tests. by Wenbin Wu (292223)

Subjects:

Parameters for the treadmill during the testing phase. by Wenbin Wu (292223)

Subjects:

Transcriptome sequencing enriched sarcopenia related GO Biological process (BP) and Molecular function (MF). Enriched GO BP of DEGs. by Wenbin Wu (292223)

Subjects:

HE staining of the gastrocnemius muscle. by Wenbin Wu (292223)

Subjects:

qPCR verified the expression changes of GO and KEGG pathway enriched sarcopenia related DEGs. by Wenbin Wu (292223)

Subjects:

Brain regions with significant metabolic inhibition (p < 0.001, K = 50) (A) and activation (B) in rats following cocaine self-administration compared to baseline. Cluster location... by Christopher Rowan (21499924)

The loss of bone in the femoral distal epiphysis is affected by housing type and weightlessness conditions in microgravity. by Rukmani Cahill (20939813)

“…Interestingly, (C) Tb.Th. is not affected by age, cage type, or spaceflight, however age and spaceflight significantly increase (D) Tb.Sp (E) Tb.Pf is only effected in FL. …”

<i>efgA</i> and <i>ttmR</i> affect the transition to methylotrophy independently. by Zachary T. Hying (21512605)

Socio-demographic and medical characteristics of patients with liver cancer. by Ayana Ablayeva (22103708)

Subjects:

Data cleaning and preparation algorithm. by Ayana Ablayeva (22103708)

Subjects:

Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. by Ayana Ablayeva (22103708)

Subjects:

Association between socio-demographic and medical parameters and all-cause mortality rates of liver cancer between 2014 and 2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and stage-specific incidence rate of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects:

Crude and age-specific mortality to incidence ratios of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

Subjects: